Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2

Conditions

Neoplasms 9Sarcoma 5Recurrence 5Neoplasm Metastasis 5Lymphoma 5Breast Neoplasms 5Endometrial Neoplasms 4Ovarian Neoplasms 3Solid Tumors 2Prostatic Neoplasms 2Multiple Myeloma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Solid Tumor 1Primary Myelofibrosis 1Osteosarcoma 1Myelodysplastic Syndromes 1Liposarcoma 1Leukemia 1Leiomyosarcoma 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Bone Neoplasms 1Advanced Cancers 1

Interventions

Dexamethasone 809Bortezomib 449Lenalidomide 430Cyclophosphamide 336Melphalan 251Calcium Dobesilate 237daratumumab 218pomalidomide 202carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67isatuximab 64Prednisone 64dexamethasone 21-phosphate 63elotuzumab 60auricularum 57belantamab mafodotin 55Antilymphocyte Serum 55Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Multiple Myeloma × ridaforolimus × Clear all
NCT00060632 2015-08-27

Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 1 Completed
46 enrolled
LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Neoplasms

NCT00060645 2015-08-27

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 1 Completed
33 enrolled
LymphoidPlasma cell

Lymphoma, Multiple Myeloma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡